PHS
PFM Health Sciences Portfolio holdings
AUM
$1.15B
This Quarter Return
+15.75%
1 Year Return
+21.39%
3 Year Return
+130.75%
5 Year Return
+265.32%
10 Year Return
+1,236.5%
AUM
$1.89B
AUM Growth
+$1.89B
(+15%)
Cap. Flow
-$4.11M
Cap. Flow
% of AUM
-0.22%
Top 10 Holdings %
Top 10 Hldgs %
39.85%
Holding
93
New
19
Increased
21
Reduced
14
Closed
17
Top Buys
| 1 |
Outset Medical
OM
|
$131M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
$41.4M |
| 3 |
NVRO
NEVRO CORP.
NVRO
|
$29.8M |
| 4 |
Avantor
AVTR
|
$28.6M |
| 5 |
Gilead Sciences
GILD
|
$25.6M |
Top Sells
| 1 |
IMMU
Immunomedics Inc
IMMU
|
$156M |
| 2 |
McKesson
MCK
|
$50.5M |
| 3 |
Cardinal Health
CAH
|
$45.2M |
| 4 |
Labcorp
LH
|
$31.4M |
| 5 |
Baxter International
BAX
|
$25.4M |
Sector Composition
| 1 | Healthcare | 77.72% |
| 2 | Technology | 5.64% |
| 3 | Consumer Discretionary | 1.62% |
| 4 | Industrials | 0.9% |
| 5 | Utilities | 0.69% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Merck
MRK
$210B
| – | – |
0
| – | – |
|
|
77
McKesson
MCK
$85.9B
| – | – |
-329,175
| Closed | -$50.5M |
|
78
Johnson & Johnson
JNJ
$429B
| – | – |
-77,167
| Closed | -$10.9M |
|
79
iShares Russell 2000 ETF
IWM
$66.6B
| – | – |
0
| – | – |
|
80
Immunovant
IMVT
$2.91B
| – | – |
-67,163
| Closed | -$1.64M |
|
|
IGMS
81
DELISTED
IGM Biosciences
IGMS
| – | – |
-115,988
| Closed | -$8.47M |
|
82
Halozyme
HALO
$8.75B
| – | – |
-597,545
| Closed | -$16M |
|
83
iShares China Large-Cap ETF
FXI
$6.65B
| – | – |
0
| – | – |
|
84
Exact Sciences
EXAS
$9.33B
| – | – |
-161,679
| Closed | -$14.1M |
|
85
Quest Diagnostics
DGX
$20.1B
| – | – |
-88,933
| Closed | -$10.1M |
|
86
Coherus Oncology, Inc. Common Stock
CHRS
$146M
| – | – |
-411,727
| Closed | -$7.35M |
|
|
87
Cardinal Health
CAH
$36B
| – | – |
-865,933
| Closed | -$45.2M |
|
|
88
Baxter International
BAX
$12.1B
| – | – |
-295,222
| Closed | -$25.4M |
|